Equities analysts expect that Synergy Pharmaceuticals Inc (NASDAQ:SGYP) will report earnings of ($0.19) per share for the current quarter, Zacks reports. Two analysts have made estimates for Synergy Pharmaceuticals’ earnings, with estimates ranging from ($0.19) to ($0.18). Synergy Pharmaceuticals reported earnings of ($0.31) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 38.7%. The firm is expected to report its next quarterly earnings report on Wednesday, March 7th.

On average, analysts expect that Synergy Pharmaceuticals will report full year earnings of ($1.03) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($1.02). For the next fiscal year, analysts forecast that the business will post earnings of ($0.54) per share, with EPS estimates ranging from ($0.62) to ($0.48). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that cover Synergy Pharmaceuticals.

Synergy Pharmaceuticals (NASDAQ:SGYP) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.06. The company had revenue of $5.01 million during the quarter, compared to the consensus estimate of $4.53 million. During the same quarter in the prior year, the company posted ($0.22) earnings per share.

Several equities research analysts have recently weighed in on SGYP shares. Canaccord Genuity set a $13.00 price objective on Synergy Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, November 12th. HC Wainwright set a $7.00 price objective on Synergy Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, December 4th. Citigroup lowered Synergy Pharmaceuticals to a “market perform” rating in a research note on Friday, January 5th. BidaskClub upgraded Synergy Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, December 22nd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $10.00 price objective on shares of Synergy Pharmaceuticals in a research note on Tuesday, November 21st. Two analysts have rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $8.38.

Synergy Pharmaceuticals (NASDAQ SGYP) traded up $0.13 during mid-day trading on Friday, hitting $2.40. The stock had a trading volume of 5,344,694 shares, compared to its average volume of 5,128,799. Synergy Pharmaceuticals has a 52 week low of $1.68 and a 52 week high of $7.15. The company has a market cap of $591.98, a price-to-earnings ratio of -2.07 and a beta of 1,040.57. The company has a debt-to-equity ratio of -68.13, a quick ratio of 3.88 and a current ratio of 4.26.

In other news, major shareholder Paulson & Co. Inc. sold 8,750,000 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $2.82, for a total value of $24,675,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 3.80% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System boosted its holdings in shares of Synergy Pharmaceuticals by 0.9% in the 2nd quarter. California State Teachers Retirement System now owns 401,730 shares of the biopharmaceutical company’s stock worth $1,788,000 after acquiring an additional 3,686 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Synergy Pharmaceuticals by 13.9% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 32,018 shares of the biopharmaceutical company’s stock worth $142,000 after acquiring an additional 3,900 shares in the last quarter. Amalgamated Bank boosted its holdings in shares of Synergy Pharmaceuticals by 16.9% in the 2nd quarter. Amalgamated Bank now owns 28,074 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 4,061 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Synergy Pharmaceuticals by 11.2% in the 2nd quarter. Principal Financial Group Inc. now owns 41,507 shares of the biopharmaceutical company’s stock worth $185,000 after acquiring an additional 4,164 shares in the last quarter. Finally, Advisor Group Inc. boosted its holdings in shares of Synergy Pharmaceuticals by 25.2% in the 2nd quarter. Advisor Group Inc. now owns 25,625 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 5,150 shares in the last quarter. 60.42% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/1817108-2/1817108.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Get a free copy of the Zacks research report on Synergy Pharmaceuticals (SGYP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.